Real-world First-line Serplulimab-based Immunochemotherapy for Extensive-stage Small Cell Lung Cancer
Real-world First-line Serplulimab-based Immunochemotherapy for Extensive-stage Small Cell Lung Cancer
Active, not recruiting · NCT06748495 · Registry updated 2025-02-27Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Real-world First-line Serplulimab-based Immunochemotherapy for Extensive-stage Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Active, not recruiting | Not stated | 2025-02-27 | NCT06748495 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Hunan Cancer Hospital | 66 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Hunan Cancer Hospital | Changsha | China | 87 |